Harnessing preclinical mouse models to inform human clinical cancer trials by Gutmann, David H et al.




Harnessing preclinical mouse models to inform
human clinical cancer trials
David H. Gutmann
Washington University School of Medicine in St. Louis
Kim Hunter-Schaedle
Children's Tumor Foundation, New York
Kevin M. Shannon
University of California - San Francisco
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Gutmann, David H.; Hunter-Schaedle, Kim; and Shannon, Kevin M., ,"Harnessing preclinical mouse models to inform human clinical
cancer trials." The Journal of Clinical Investigation.116,4. 847-852. (2006).
http://digitalcommons.wustl.edu/open_access_pubs/1562
Review
	 The	Journal	of	Clinical	Investigation      http://www.jci.org      Volume 116      Number 4      April 2006  847
Harnessing preclinical mouse models  
to inform human clinical cancer trials
David H. Gutmann,1 Kim Hunter-Schaedle,2 and Kevin M. Shannon3
1Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.  








































































Opportunities to employ mouse models
The availability of robust GEM models facilitates a detailed analy-
sis of human cancer that cannot be easily accomplished by study-
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and early  response  to  therapy, which would have  tremendous 
impact on current treatment strategies, is another unmet need.





















chromosomal translocations that fuse the retinoic acid receptor alpha 
(RARA) gene to a variety of partner genes including promyelocytic 
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Performing preclinical studies in mice



























Using GEM cancer models to investigate responsiveness and resistance 
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Use of GEM tumor models as “filters” to select agents for human clini-
cal trials. One strategy has been proposed for use in the Nf1 GEM 
models community, which involves the evaluation of new therapies in 
multiple mouse strains. New drugs would be rapidly screened using 
MPNST and leukemia GEM models for efficacy (therapeutic index), 
target validation, and potential “off-target” effects. These GEM models 
would be utilized for initial evaluation, based on the rapid growth of the 
tumors and the relative ease of measuring tumor growth. Drugs that 
exhibit activity in these models would be further analyzed in detailed 
PK/PD studies in other tumor models, such as orthotopic tumor explant 
models and transgenic mice harboring specific deregulated cancer-
associated molecules or pathways. Optic glioma and neurofibroma 
(plexiform neurofibroma) GEM models may be better suited for che-
moprevention studies as well as investigations of drugs that target 
specific cells in the tumor microenvironment (e.g., microglia and mast 
cells). Collectively, the combined use of each of the available robust 
preclinical GEM models would afford researchers the opportunity to 
comprehensively evaluate drugs prior to considering human clinical 
trials. Adapted with permission from a summary presentation by Susan 
Blaney, Cold Spring Harbor Laboratories, Banbury Center conference 
on “Barriers and Solutions in the Use of Mouse Models to Develop 
Therapeutic Strategies for Neurofibromatosis-Associated Tumors,” 
November 3–5, 2005.
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